; (B) not later than 180 days after the close of the period for public comment on the revision proposed under subparagraph (A), publish a final revision to such final rule; and (C) not later than 180 days after the date of enactment of this Act, publish a plan for monitoring industry compliance with the rules, regulations, and guidance of the Food and Drug Administration relating to GRAS, including the December 2022 guidance titled Best Practices for Convening a GRAS Panel . (2) Contents The revision required by subparagraphs (A) and (B) of paragraph (1) shall include each of the following: (A) The revision shall prohibit a manufacturer from marketing a substance as GRAS, or manufacturing or selling food that contains a substance the manufacturer has determined to be GRAS, unless— (i) the Secretary has made a final determination, which is conveyed to the manufacturer in writing, that the Secretary has received sufficient notice from the manufacturer that the manufacturer has determined such substance to be GRAS under the conditions of its intended use; and (ii) the manufacturer has provided the Secretary with supporting information sufficient to understand the basis of the determination, including— (I) the cumulative effects of the substance, as required under section 409 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 348 ); (II) an adequately protective use of safety factors, as described under such section 409, including safety factors to account for the particular sensitivities of vulnerable human populations, to the extent that data are available to derive safety factors for each vulnerable human population; (III) information demonstrating that the weight of evidence analysis shows the substance has not been found to induce cancer when ingested by humans or animals